Ascletis, Inc. Names Allan Baxter, PhD, Former GlaxoSmithKline Global Head of Medicines Development, as Chief Strategy Officer

RESEARCH TRIANGLE PARK, N.C. & HANGZHOU, China--(BUSINESS WIRE)--Ascletis, Inc., a U.S.-China pharmaceutical company developing important medicines for cancer and infectious diseases, today announced the appointment of Allan Baxter, Ph.D. as Chief Strategy Officer. Dr. Baxter, who has been an advisor to Ascletis since its founding, joins Ascletis following a 30 year career at GlaxoSmithKline (GSK), where he ultimately served as Senior Vice President and Global Head of Medicines Development with accountability for GSK’s late-stage drug development pipeline.